Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine - Wikidata - awgldk - TriplyDB

Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine

Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine

http://www.wikidata.org/entity/Q36827128

about

Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach Production of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific Antibodies Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer.Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody.Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies Progress and prospects for L2-based human papillomavirus vaccines Characterization of serum antibodies from women immunized with Gardasil: A study of HPV-18 infection of primary human keratinocytes Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.Model systems to study the life cycle of human papillomaviruses and HPV-associated cancers.Developments in L2-based human papillomavirus (HPV) vaccines.Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types.Broadly neutralizing antiviral responses induced by a single-molecule HPV vaccine based on thermostable thioredoxin-L2 multiepitope nanoparticles.Roles of Fc domain and exudation in L2 antibody-mediated protection against human papillomavirus.

P2860

Q28607775-66863130-A7F4-4FD8-9E3E-4DE7BC95A70B Q28611356-E50F9E02-E2BF-4A50-AFBF-EA5D7D2B2957 Q33591582-16D43B9B-105A-4534-93A5-BA7ABD059777 Q33856453-91177731-D64D-4712-B9B9-02E60E4B0F15 Q34822738-DDE9C0E7-8435-4E5A-84E4-E89EE0B5219C Q35095954-FE14AEBE-513D-4C77-B3F4-25EA74127FC5 Q35532771-6E640BCE-48C6-4030-9193-4A91643A18EE Q35773930-C25B2D70-BA1E-4E9F-A0CC-EE986FA09BF3 Q37014047-BF006A2F-D554-46E2-9EFC-58E18DD19ED6 Q37180418-E31529F5-942F-4AF9-AC96-A63E61C38247 Q37599123-89712F1F-1B57-49CE-9602-AA908235DC19 Q38449589-99145D44-A1FB-44D4-B375-17FEE7C9EB3D Q39021001-A049E71C-0B21-4C16-8AB6-4D5BC0D06965 Q41926367-AD62FAF2-0582-4F30-B28F-DA2C02DDE23A Q47110564-08CC65AA-7E4E-45A9-852A-85C0AF2CCE7E Q54216752-797B58FE-4563-4E34-978E-66D509E442A2

P2860

Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine

http://www.wikidata.org/entity/Q36827128

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine

@en

type

label

Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine

@en

prefLabel

Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine

@en

P1433

Q36827128-DF010F99-6A7F-40F7-AA20-857849629B30

P1476

Q36827128-3B01F887-371D-4AEE-A1B6-54A0DAE29D6F

P2093

Q36827128-155FCDD2-434A-4932-A002-16CB4648CA43

Q36827128-16FA686F-E106-48DC-BBC1-36A9EFCD4DAE

Q36827128-1D146BAA-E5C2-4D1D-A427-6BBB4A3ABA01

Q36827128-38E6E907-E286-4797-BAF2-8DFFAB6CBB7B

Q36827128-48958574-B7D2-455A-B7EC-178DDC727E35

Q36827128-5BD3291F-052C-49C0-A254-200D4DBB1DD8

Q36827128-5E90FD69-6E9F-4260-AA03-D74D9CDCA35B

Q36827128-65EEEB7A-4C07-48A9-B453-21C952A58736

Q36827128-69CAEA40-3F31-4D10-BCC0-738B2378904F

Q36827128-6EA863D1-9698-4CC8-B7F4-8BCA428BFFA5

P2860

Q36827128-05DB1D74-3C75-4D2F-B269-250A19C2739C

Q36827128-10E2398D-3F61-401E-8B21-3843842746DD

Q36827128-1210E471-4DC1-42E7-9F70-2F6B1448529C

Q36827128-1A99C560-EE44-4FAB-916B-80F2388EFA7A

Q36827128-1EE4CC4F-CC6C-4806-ACCB-1A5356B44935

Q36827128-23EE234D-37D1-4E6E-9E0D-E002FFD3E3EC

Q36827128-278514FC-E2CF-4001-82F0-9F40892FC106

Q36827128-352D94D5-41E5-4644-AEA7-C9BE46E92465

Q36827128-5018A064-5BB9-4152-B473-7DC1C0D8150C

Q36827128-5995CA4B-26CC-4518-88FD-884CB483C30A

P304

Q36827128-17DCD6AA-5C7D-4FD1-847E-D3AF27F0DAED

P31

Q36827128-2878293F-7554-42BF-BCE9-568DCB533D77

P356

Q36827128-1D8CB473-E836-4FB4-AF1A-95827F780F40

P407

Q36827128-E8942825-BE66-4FB4-B169-0F2555F6228F

P433

Q36827128-8218A5A2-F836-4534-8B22-69109F10F44B

P478

Q36827128-B69E02FB-1C53-4E0A-809B-2EDE3C8F9A69

P577

Q36827128-55100A49-D590-4B51-9467-C7FD0CDCC5CB

P698

Q36827128-40485B56-8CD8-4D8F-8D36-E7FFB6987EC6

P921

Q36827128-90E73631-91EC-49BD-AA4C-93C792A5CD51

P932

Q36827128-D5C5CDC8-C5A2-4DDC-B117-1BF0FB0798D3

P356

P1433

Journal of Virology

P1476

Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine

@en

P2093

Chenguang Wang

http://www.w3.org/2001/XMLSchema#string

Douglas R Lowy

http://www.w3.org/2001/XMLSchema#string

Harold Kleanthous

http://www.w3.org/2001/XMLSchema#string

Hsu-Kun Wang

http://www.w3.org/2001/XMLSchema#string

John T Schiller

http://www.w3.org/2001/XMLSchema#string

Kihyuck Kwak

http://www.w3.org/2001/XMLSchema#string

Kilvani S Jaganathan

http://www.w3.org/2001/XMLSchema#string

Kirill Kalnin

http://www.w3.org/2001/XMLSchema#string

Louise T Chow

http://www.w3.org/2001/XMLSchema#string

Richard B S Roden

http://www.w3.org/2001/XMLSchema#string

P2860

Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6

Cross-neutralization potential of native human papillomavirus N-terminal L2 epitopes.

Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.

Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments

In vivo mechanisms of vaccine-induced protection against HPV infection.

Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.

P304

6127-6136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.03218-12

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23536682

http://www.w3.org/2001/XMLSchema#string

P921

P932

3648087

http://www.w3.org/2001/XMLSchema#string